Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-09-21
This disclosure announces a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for EU approval of Klygefa (gefurulimab) for treating generalised myasthenia gravis. The announcement details successful Phase III trial results (PREVAIL) meeting primary endpoints and describes the drug's mechanism and market opportunity. This is a material regulatory milestone for a rare disease therapeutic that, if approved, would be the first dual-binding nanobody C5 inhibitor in the EU for this indication—a significant operational and commercial achievement for AstraZeneca's Alexion subsidiary, though not a discrete event type like M&A, earnings, or executive change.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-21
Item 7.01
The Company executed a non-binding term sheet for assignment of contract-use, offtake, deployment, and device-design rights into a newly formed Indonesian subsidiary (PTVCI), in which the Company will hold 99% equity interest. The transaction is subject to multiple closing conditions including export approvals, Indonesian regulatory approvals, third-party consents, and board authorization, with anticipated consideration via Series F Preferred Stock issuance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.5
CordovaCann announced a strategic decision to exit cannabis retail operations in Oregon and Washington and divest assets in both states, while expanding Star Buds Cannabis Co. retail operations in Canada. This represents a material shift in the company's geographic footprint and business focus.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.25
CordovaCann opened its sixth Star Buds cannabis retail store in Canmore, Alberta, marking the company's entry into a third Canadian province. The disclosure included January-February 2021 revenues of $1.7M with 35.7% gross margin across five stores.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.29
CordovaCann's subsidiary received regulatory approval to operate as a cannabis retailer in Alberta (up to 64 stores) and opened the first Star Buds retail locations, with December revenue of $1.066M and 35.1% gross margin. This represents a material operational and strategic development affecting the company's growth trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-21
EX-99.32
CordovaCann's subsidiary Cannabilt Farms was granted a Marijuana Production License from the Oregon Liquor Control Commission, enabling cultivation of cannabis on a 6-acre facility in Clackamas County. The company has invested over $2.4 million in the facility and expects to begin full cultivation by Summer 2021.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.35
CordovaCann opened two Star Buds retail store locations in Barrie and Bradford, Ontario, following the April 2020 acquisition of Star Buds retail assets. The company issued 6 million common shares (3 million per store) as consideration for this operational expansion.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-21
EX-99.36
CordovaCann opened its first Star Buds branded cannabis retail store in Ontario, specifically in Barrie, following regulatory approval from the Alcohol and Gaming Commission of Ontario. This represents a material operational milestone and the beginning of a planned multi-store expansion strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-16
Item 8.01
The filing discloses orders for nine ROSA units with SARA licensing—six units from a major national automotive retailer (first order from this customer) and three units from an existing construction customer (repeat order). This represents a material operational and commercial milestone: entry into a new major customer segment (automotive) and expansion of an existing customer relationship. The press release emphasizes ROSA's role as foundational to the company's stationary security platform and recurring revenue growth. While not a formal earnings release, the disclosure of significant new customer orders and their expected deployment timing is material to investors assessing the company's commercial traction and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
New Found Gold declares commercial production at its Hammerdown Gold Mine, a major operational milestone achieved on August 19, 2026, after meeting three sustained criteria (throughput, gold recovery, feed grade) over 60 consecutive days. This is a material operational event marking the transition from development to production phase, with disclosed production of 9,140 ounces in the first eight months of 2026 and expected run rates of 20,000–25,000 oz Au annually. While not fitting the specific categories of earnings release (no financial results disclosed), M&A activity, or workforce reduction, this represents a significant operational achievement that would materially affect a reasonable investor's assessment of the company's progress toward becoming a mid-tier gold producer.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
Liberty Defense announced a multi-site commercial deployment agreement with a third-party logistics and manufacturing provider to deploy two HEXWAVE systems in 2026 and additional systems projected for 2027. This represents a material operational milestone—entry into the commercial loss-prevention market segment with a significant customer contract—but does not fit the specific event categories of M&A, debt issuance, or other named types. The disclosure emphasizes the strategic importance of this customer as "a strong fit for HEXWAVE and represents the kind of commercial market the technology was built to serve," indicating materiality to investors assessing the company's market expansion and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
This press release discloses operational and contracting updates for Borr Drilling's jack-up rigs: the Odin commenced earning dayrate revenues on September 11, 2026 following mobilization and acceptance testing; the Idun was awarded a three-well contract in Vietnam commencing Q4 2026; and ENI exercised a nine-month option extending the Bestla contract to September 2027. These are material operational milestones and new contract commitments that would affect a reasonable investor's assessment of the company's revenue-generating capacity and backlog, but they do not constitute a discrete M&A transaction, earnings release, or other specifically-named event type—they are operational and strategic business developments.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
This press release announces successful validation of IperionX's GenX™ continuous titanium production platform, a material operational and technological milestone. The disclosure details achievement of continuous HAMR™ processing with significant measured improvements: 6x throughput, >75% lower power consumption, >45% less magnesium, and >60% less hydrogen per kilogram versus batch production. All product samples met relevant ASTM oxygen specifications. This represents a material advancement in the company's core production technology and cost structure that would affect a reasonable investor's assessment of operational capability and future economics, though it does not fit the specific categories of earnings release, M&A activity, impairment, or other named event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
This press release announces preliminary engineering results (FEL-1) for a proposed two-phase nickel refinery and battery recycling facility, with first-phase capital estimates of US$530–675 million for 20,000 tonnes annual nickel production. The disclosure describes a material strategic expansion into nickel refining and recycling—a significant operational and capital initiative that would strengthen the company's critical minerals processing portfolio. While not a discrete M&A transaction, financing event, or earnings announcement, this represents a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's growth trajectory and capital allocation plans.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.1
Optimi announces plans to initiate a Health Canada-authorized Phase 3 clinical trial for MDMA-assisted therapy in PTSD, expected to begin in 2027 with enrollment of up to 100 participants. This represents a material advancement of the company's clinical pipeline and regulatory strategy in psychedelic-assisted therapies, directly supporting the company's stated goal of submitting both MDMA and psilocybin products for registration. While not a discrete M&A event, covenant breach, or financial transaction, this clinical milestone is operationally significant to a pharmaceutical manufacturer's value proposition and would affect a reasonable investor's assessment of the company's progress toward commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-16
EX-99.1
PRF Technologies announced that GridFeed™, its AI-driven energy optimization platform, is exploring the AI and hyperscale data center market as a strategic growth opportunity. This is a material operational and strategic initiative—the company is pivoting its GridFeed technology into a new market segment (data centers) with significant growth potential (IEA projects data center electricity consumption to triple by 2030). The announcement also references the September 9, 2026 plan to establish GridFeed as a standalone wholly owned subsidiary, which supports the strategic nature of this market expansion. While this is clearly an operational/strategic business development rather than a discrete event like M&A, earnings, or executive change, it represents a material shift in business direction that would affect a reasonable investor's assessment of the company's growth prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-16
Item 8.01
The disclosure announces the Japan Patent Office's grant of Japanese Patent No. 7917283 covering Allarity's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with protection extending to 2039. This is a material intellectual property milestone for a clinical-stage pharmaceutical company, as it strengthens patent protection in Japan—described as "one of the world's largest pharmaceutical markets"—and supports the company's development and commercialization strategy for stenoparib. While this is an operational/strategic event (intellectual property protection), it does not fit the specific categories of earnings release, executive changes, M&A, impairment, litigation, or other named event types, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-16
EX-99.1
RoyaLand announces a partnership with NipsApp Game Studios to develop three new mobile games (Regalia Cards, Palazzo Chronicles, and Viva Verdi) targeting October 2026 launch. This represents a material expansion of the Company's mobile entertainment presence and a strategic extension of its royalty-themed brand ecosystem. While not a discrete M&A transaction, covenant breach, or other named event type, this product-development and partnership announcement is a significant operational milestone that would affect a reasonable investor's assessment of the company's business strategy and near-term revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-16
EX-99.2
Draganfly announced a five-year contract award from the Government of Canada to supply Low-Cost Tactical ISR Uncrewed Aircraft Systems to the Canadian Armed Forces, with an initial firm commitment for 100 systems and options for up to 4,900 additional systems valued at approximately C$24.25 million.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-16
Co-Diagnostics announced a collaboration with ReadyGo Diagnostics to evaluate blood-based molecular testing using combined technologies, with initial focus on Ebola detection. This is a material strategic partnership that could substantially broaden the Co-Dx PCR platform's applications into bloodborne pathogens (HIV, hepatitis B and C) and represents a significant expansion of the company's addressable market. While not a formal M&A transaction, the collaboration is a material operational and strategic development disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
Korn Ferry disclosed a realignment of its organizational reporting structure from solution-based to geographic segments (Americas, EMEA, Asia Pacific) effective May 1, 2026, and furnished recast unaudited quarterly fee revenue for fiscal 2026 under the new structure. This is a material operational/strategic restructuring of how the company reports and organizes its business, though the filing explicitly states it is not a financial restatement and does not affect GAAP consolidated results. The disclosure is operational in nature—reflecting a change in how the company delivers services and aligns with its operating model—rather than a routine administrative matter.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
The exhibit discloses two distinct operational developments: (1) a material update on Houdini Swap's trading volume growth (14% increase from June to August 2026, reaching ~US$74 million monthly), demonstrating business traction and product adoption; and (2) an executive role change for Stephen Ehrlich from Chief Strategy Officer to Director of Capital Markets. The volume metrics and growth trajectory are operationally significant to a digital asset infrastructure company's valuation and strategy, while the executive transition is a governance matter. Neither fits a single named category—the volume update is not a discrete earnings release (it is preliminary, unaudited operational metrics, not formal financial results), and the executive move is a lateral role change rather than a departure or appointment to a new position. Together, these constitute material operational and strategic updates.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
Scholar Rock disclosed FDA approval of ISEMBYLD for spinal muscular atrophy, a significant regulatory and commercial milestone. The disclosure also corrects a management misstatement regarding post-marketing safety commitments, specifically pregnancy safety studies and fracture reporting requirements. This is a material operational/regulatory event involving product approval and compliance obligations, but does not fit the specific categories of earnings release, M&A, restatement, or other named types. The correction of the erroneous statement and the FDA's post-marketing requirements are operationally and commercially significant to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
This exhibit announces the delivery and acquisition of a new 64,000 DWT Ultramax dry bulk vessel ("Glbs Olympia"), expanding Globus's fleet from nine to ten vessels with total capacity of 744,622 DWT. While the acquisition was previously announced on August 23, 2023, this disclosure marks the completion and delivery of a material capital deployment event that strengthens the company's operational fleet and is consistent with its stated fleet renewal strategy. This is an operational/strategic milestone rather than a discrete M&A event (which would apply to the original acquisition announcement), making it an operational event material to investors assessing the company's growth trajectory and asset base.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
This disclosure announces FDA alignment on key clinical trial parameters for RP-A501 in Danon disease, including confirmation of a 12-patient pivotal population, recalibrated dose, and 12-month co-primary endpoints intended to support accelerated approval. While this is a material regulatory and clinical milestone affecting the company's development pathway, it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined financial/legal/governance event). The event is clearly operational—a significant clinical development milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
This press release announces a significant permitting milestone for Anfield's JD-8 uranium and vanadium mine: the Colorado Division of Reclamation, Mining and Safety (DRMS) has issued a completeness determination and staff recommendation for Board approval of the mine permit, with a formal Board hearing scheduled for October 14–15, 2026. The disclosure describes this as "a significant de-risking event" and "a major permitting milestone" that advances the company's operational strategy toward domestic uranium production. While the event is operational and strategic in nature (mine permitting progress), it does not fit neatly into the specific operational categories (no material contract, partnership, or product launch is disclosed—rather, a regulatory approval milestone). The materiality is clear: a reasonable investor would view state-level permitting approval and a defined Board decision window as material to the company's ability to execute its production strategy and timeline (targeted Q2 2027 restart).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
OMNIQ announced receipt of U.S. Patent No. 12,633,155 B1 for AI-based vehicle occupancy detection technology for HOV lane enforcement. The press release emphasizes the patent's commercial significance, citing a representative deployment generating ~$1.6M annually and a total addressable U.S. market of ~$218M across 136 facilities. This is a material operational and strategic milestone—a patented technology with identified market opportunity and existing deployments at two U.S. and one international site—but does not fit the specific categories of earnings, M&A, debt, impairment, or other named event types. The disclosure is clearly operational/strategic rather than financial or governance in nature.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
ParaZero announced a non-binding Memorandum of Understanding with ThirdEye Systems to develop an integrated Counter-UAS solution combining detection and physical interception capabilities. While this is a strategic partnership announcement rather than a completed M&A transaction, it represents a material operational and commercial development that would affect a reasonable investor's assessment of the company's product roadmap, market positioning, and growth prospects in the defense sector. The MOU is non-binding and subject to definitive documentation, which distinguishes it from a binding acquisition or merger (ma_activity), making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
Ingram Micro disclosed its inaugural Capital Markets Day event on September 15, 2026, where management outlined a long-term strategic transformation into a "B2B intelligent operating system" and introduced a multi-year financial framework (FY2026-2029E) with specific targets for net sales CAGR (~4-6%), gross profit CAGR (~5-7%), non-GAAP net income CAGR (~11-13%), and adjusted ROIC (~16-17%). While the filing reaffirms Q3 FY2026 guidance, the principal disclosure centers on the company's strategic direction, platform transformation (Xvantage™), and forward-looking financial targets rather than a discrete operational event like a restructuring or material contract. This is a strategic and financial outlook disclosure that would be material to investors assessing the company's long-term value creation plan.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
Vera Therapeutics announced positive final efficacy analysis results for TRUTAKNA in the ORIGIN 3 Phase 3 trial for IgA nephropathy, demonstrating that the drug met all prespecified endpoints including 76% risk reduction in composite kidney disease progression and stabilization of eGFR through 104 weeks. The company plans to submit a supplemental BLA for full approval in Q4 2026 based on these results, with strong early commercial launch momentum reported.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
BlossomHill disclosed updated Phase 1/2 clinical trial data for its lead candidate BH-30643, including a 45% objective response rate and 88% disease control rate in EGFR C797S-positive NSCLC patients, presented at IASLC 2026. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, demonstrating progress toward regulatory advancement (the drug has received FDA Fast Track designation and the company plans to initiate a Phase 2 study in Q1 2027). While not a traditional earnings release or M&A event, the positive clinical efficacy and safety data constitute a material business development milestone that would affect a reasonable investor's assessment of the company's pipeline and prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
This press release announces the successful launch of the final three O3b mPOWER satellites, completing SES's second-generation MEO constellation. The disclosure is a material operational milestone—the completion of a major satellite constellation that expands the company's core connectivity service capacity and capabilities. While not a discrete financial event (earnings, debt, M&A), it is a significant strategic and operational achievement that would affect a reasonable investor's assessment of SES's ability to deliver on its MEO network strategy and serve customers globally.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
Coya Therapeutics announced enrollment of the 100th patient in its Phase 2/3 ALSTARS Trial for COYA 302 in ALS treatment, with anticipated topline data in early Q2 2027. This is a material clinical development milestone for a biopharmaceutical company with a lead product candidate, affecting investor assessment of pipeline progress and regulatory pathway advancement. While not fitting a specific named event type, this is clearly an operational/strategic milestone disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 1.01
Aligos entered into a First Amendment to its headquarters lease on September 10, 2026, extending the term from March 31, 2027 to March 31, 2034 with specified rent escalations and a ten-month rent abatement. While this is a material definitive agreement affecting the company's long-term occupancy of its headquarters, it is primarily an operational/real estate matter rather than a financial obligation (debt issuance), M&A activity, or other specifically-named event type. The lease extension secures the company's primary office location for seven additional years and would be material to investors assessing operational continuity, but the event itself is a routine real estate transaction that does not fit the more specific financial or strategic categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
The disclosure announces initial assay results from the 2026 infill and expansion drilling program at the Kitsault Valley Project, highlighting high-grade silver intercepts (506 g/t AgEq over 13.90m at Torbrit; 807 g/t AgEq over 4.96m at North Star) and confirming a mineralized connection between two deposits. This is an exploration milestone and operational update material to investors assessing the project's development potential, but it does not fit the specific categories of earnings release, M&A activity, impairment, or other defined event types. The results represent progress on a material exploration asset and would affect a reasonable investor's assessment of the registrant's resource base and mine-planning prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 74%
filed 2026-09-15
Item 7.01
Beta Bionics announced FDA clearance of Mint, a patch pump product, and submission of a 510(k) application for 3D Intelligence, its next-generation insulin dosing algorithm. The company provided commercialization timelines (Q1 2027 for Mint, end of 2026 for iLet 3D), manufacturing capacity expectations (1.5 million units in 2027), and revised 2026 revenue guidance downward to $121–$126 million from $131–$136 million.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
This disclosure announces an investor presentation and operating update in connection with the company's participation in the BofA Securities Global Real Estate Conference. The filing provides updated Same Store Residential revenue outlook (2% at midpoint), occupancy metrics (95.7% physical occupancy), and rent growth data (3.6% year-over-year net effective asking rents). While the company recently completed a material merger (AvalonBay and Equity Residential merger closed August 17, 2026), this Item 7.01 disclosure focuses on operational performance metrics and guidance rather than the merger itself, making it an operational disclosure. The material nature is supported by the provision of forward guidance and performance metrics that would inform investor assessment of the combined company's trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
This press release announces the successful completion of the first phase of SaverOne's Driver Distraction Prevention System (DDPS) installation in Cemex Germany's truck fleet, with plans for further rollout. The disclosure represents a material operational and commercial milestone—expansion of a key customer relationship and European footprint—but does not fit the specific event categories (earnings, M&A, executive changes, debt, etc.). It is a material business development that would affect a reasonable investor's assessment of SaverOne's commercial traction and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
This press release announces a licensing collaboration between Rice AI (Mint's indirect majority-owned subsidiary) and Pudgy Penguins to develop and commercialize a co-branded "Blue Pengu Minibot" AI-powered robot. The agreement grants Rice AI a non-exclusive, worldwide license to design, produce, and sell the product through e-commerce and retail channels. This represents a material strategic partnership and product launch in the consumer robotics space, aligning with Mint's stated focus on AI and robotics. While not a traditional M&A transaction, the licensing deal and resulting product commercialization constitute a significant operational and commercial milestone that would affect a reasonable investor's assessment of the company's business strategy and revenue opportunities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
The filing discloses an investor presentation posted on September 14, 2026, under Item 7.01 (Regulation FD Disclosure). The presentation details Spectral AI's FDA De Novo clearance (May 2026), BARDA contract status ($150M total with $31.7M exercised), commercial launch strategy, and financial position. While the FDA clearance itself is a regulatory milestone, the primary disclosure here is the investor presentation itself—a strategic communication about the company's product commercialization, market opportunity, and capital deployment plans. This is an operational/strategic disclosure rather than a specific event type (not earnings, M&A, litigation, etc.), making it operational_other. It is material because it communicates significant regulatory achievements, government funding, commercial milestones, and financial position to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
This press release discloses a material operational disruption: a ballistic missile strike on ArcelorMittal's Ukrainian steel plant (ArcelorMittal Kryvyi Rih) resulting in two contractor deaths, two employee injuries, and halted primary steel production pending damage assessment and repair. The strike is the second in five weeks and directly impacts the company's operational capacity and financial performance, making it material to investors. While the event involves geopolitical/military factors, the core disclosure is an operational disruption and production halt at a major facility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
EX-99.1
This news release announces drilling results from Collective Mining's Apollo deposit exploration program, specifically reporting assay results from 13 diamond drill holes testing the Shallow Halo Zone and infill drilling. The disclosure highlights the discovery of broad zones of shallow mineralization in areas previously modeled as waste, with potential to expand the mineral resource and reduce the strip ratio. While not a discrete M&A event, executive change, or financial restatement, this represents a material operational and strategic milestone for an exploration-stage mining company—the results directly support the company's stated objective to expand and infill drill Apollo and demonstrate resource growth potential beyond the maiden mineral resource announced September 8, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-15
Item 8.01
Pulse Biosciences announced completion of patient enrollment in its PRECISE-BTN clinical study for the nPulse™ Vybrance™ system, with enrollment expanded from 50 to 100 patients and the first patient completing 12-month follow-up. This is a material clinical development milestone for a medical device company, representing progress toward regulatory approval and commercialization, but does not fit the specific event categories (earnings, M&A, impairment, litigation, etc.). It is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's product development trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
NRx Pharmaceuticals received FDA notification that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from a Major Amendment to a Minor Amendment, with the GDUFA goal date revised to November 10, 2026. This is a material regulatory milestone that accelerates the approval timeline for a strategic drug-shortage product, directly affecting the company's development pathway and commercial prospects. While not fitting a specific named category, this is clearly an operational/regulatory event material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 7.01
Transocean announced a two-well contract award for the Deepwater Conqueror in Equatorial Guinea valued at approximately $80 million in backlog, commencing in 2027. This is a material operational and commercial event—a significant contract award that affects the company's revenue pipeline and fleet utilization—but does not fit the specific categories of M&A, debt issuance, earnings release, or other named event types. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and represents a material business development for a contract driller.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-15
EX-99.1
This press release announces the deployment of MMA.INC's BJJLink software platform at UFC GYM's first standalone jiu-jitsu studio location in New York (opened August 8, 2026) with a Florida location expected in January 2027. The disclosure emphasizes transition from "rollout planning into live operations" and establishment of "additional recurring software and transaction revenue opportunities," representing a material operational and commercial milestone for the partnership. While this is a business development event rather than a discrete M&A transaction, executive change, or financial event, it constitutes a material operational milestone that would affect a reasonable investor's assessment of the company's revenue growth trajectory and platform adoption.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-15
LifeMD announced an exclusive strategic collaboration with AT&T Services, Inc. whereby over 100 million eligible AT&T customers receive complimentary access to LifeMD's virtual care and pharmacy platform (valued at $228 annually). The agreement includes a multi-phase launch starting in 11 states with nationwide expansion planned for January 2027, governed by a Subscriber Health & Wellness Collaboration Agreement with an initial one-year term and automatic renewal provisions. This is a material operational and commercial partnership that significantly expands LifeMD's customer reach and market presence, though it does not fit the specific categories of M&A activity, debt issuance, or other defined event types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-15
Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics in August 2026 to evaluate compatibility of ReadyGo's sample collection and preparation technologies with the Company's Co-Dx PCR platform. The filing emphasizes the agreement is "material" and describes it as a strategic evaluation of complementary technologies to enhance the Co-Dx platform's usability in decentralized testing environments. While preliminary and non-binding, this represents a material operational/strategic partnership evaluation that would inform investors about the Company's product development trajectory and potential technology integration opportunities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-15
Item 8.01
Summit announced updated overall survival results from the Phase III HARMONi clinical trial presented at WCLC 2026, showing a statistically significant OS benefit (HR 0.76, p=0.0151) in the June 2026 data cut with longer follow-up, particularly in western patients. While this is clinical trial data rather than a traditional earnings release or regulatory approval, the positive efficacy results for ivonescimab—a lead investigational asset with a pending BLA and November 2026 PDUFA date—represent material operational/clinical progress that would affect investor assessment of the company's pipeline and regulatory prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-15
Harmony reports a fatal workplace incident at its Mponeng mine following a seismic event on September 14, 2026. This is a material operational and safety event that would affect a reasonable investor's assessment of the company's operational risk, safety controls, and regulatory standing. While not fitting a discrete named category, this is clearly an operational/safety matter requiring disclosure under Item 8.01 (Other Events) equivalent in a 6-K context.
View raw filing on EDGAR →